857 companies disclosed performance briefings in the first week of the Year of the Horse, with 4 companies experiencing net profit growth of over 10 times

Gelonghui, February 28 — According to 21 Finance, during the first week of the Year of the Horse, listed companies on the A-share market began to disclose their performance reports intensively. According to Tonghuashun iFind, as of February 28, in the first week of the Year of the Horse, 857 A-share listed companies have disclosed their 2025 performance briefings, with 470 companies reporting year-over-year increases in net profit attributable to shareholders. The industries with the strongest performance fundamentals are electronics, machinery equipment, and pharmaceuticals and biologicals, accounting for 97, 77, and 69 companies respectively.

In terms of revenue growth, Haichuang Pharmaceutical, a pharmaceutical company listed on the STAR Market, was a standout this week. The performance report shows that Haichuang Pharmaceutical achieved operating revenue of 21 million yuan in 2025, a year-over-year increase of 5536.26%. The growth mainly stems from the approval and sale of its first Class 1 new drug, Duen Zaluamide soft capsules (Project No.: HC-1119), which was approved for sale in May 2025, generating drug sales revenue.

However, in 2025, the company’s net profit attributable to shareholders still recorded a loss of 137 million yuan, though this was a reduction of 31.48% compared to the same period last year. Haichuang Pharmaceutical stated that although the product has been launched, it was only included in the national medical insurance catalog in December 2025. Factors such as price reimbursement and marketing model adjustments affected revenue recognition for the period. Additionally, the company is still in the early stages of commercialization, with significant investment in R&D and marketing, and has not yet achieved profitability.